CHAMGAP

Oral curcumin or curcuminoid supplementation × Body-weight reduction in adults with overweight or obesity

Select a review item to see its details.
Required evidence, verification status and materials actually read
ItemAVerification statusBReading scopeCReview itemDCurrent findingsEWhy unverifiedFRequired materials and conditionsGFurther research
1 Partly verified Full text not readStored summary read N01 · Evidence conditionWhich curcumin preparation and body-weight question are addressed?Required
The original claim concerns reduced body weight in kg in adults with overweight or obesity. The retained meta-analysis summary mixes conventional and enhanced formulations.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Oral curcumin, population, body weight in kg, comparison and weeks-to-months scope
Material needed: Meta-analysis eligibility/question definitions and original-trial lists. This records needed materials; no new research was executed.
2 Partly verified Full text not readStored summary read N02 · Evidence conditionWhat are the conventional and bioavailability-enhanced formulations?Required
The retained use conditions describe conventional and bioavailability-enhanced oral formulations, with piperine combinations kept separate.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Curcuma longa-derived curcumin/curcuminoids and oral-formulation classification
Material needed: Trial-specific product/composition/content tables and formulation contributions. This records needed materials; no new research was executed.
3 Partly verified Full text not readStored summary read N03 · Evidence conditionHow are piperine, diet and exercise combination effects distinguished?Required
The original keeps piperine combinations separate and warns against assigning piperine, diet or exercise combination effects to curcumin alone.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Separating curcumin alone from absorption-enhancer/lifestyle combinations
Material needed: Trial-specific composition, accompanying diet/exercise and shared-care tables. This records needed materials; no new research was executed.
4 Partly verified Full text not readStored summary read N04 · Evidence conditionAre oral supplementation, turmeric and topical oral products the same intervention?Required
The original intervention is oral curcumin/curcuminoid supplementation. It warns against treating products as interchangeable.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Distinguishing swallowed supplements from conventional turmeric, topical products and special formulations
Material needed: Original trials using the same product and route. This records needed materials; no new research was executed.
5 Partly verified Full text not readStored summary read N05 · Evidence conditionWere overweight, obesity and metabolic-disease populations distinguished?Required
The retained use conditions describe adults with overweight, obesity or obesity-related metabolic disease. The original claim concerns body weight in kg in adults with overweight or obesity.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Trial-specific weight status, obesity-related metabolic disease and baseline BMI/body weight
Material needed: Included-study populations/baseline characteristics and eligibility criteria. This records needed materials; no new research was executed.
6 Partly verified Full text not readStored summary read N06 · Evidence conditionWhat doses were used, and is an optimum established?Required
The original dose record states that doses varied across trials and no single optimum was established.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Trial-specific administered doses, constituent content, frequency and adherence
Material needed: Original-trial administration/constituent-content tables. This records needed materials; no new research was executed.
7 Partly verified Full text not readStored summary read N07 · Evidence conditionWhich weight results across weeks to months were pooled?Required
The original duration is weeks to months, varying by trial.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Trial-specific treatment duration, measurement visits and end/follow-up timepoints
Material needed: Trial-specific visits/durations, follow-up and extraction-timepoint tables. This records needed materials; no new research was executed.
8 Partly verified Full text not readStored summary read N08 · Evidence conditionWhat did placebo or control management involve?Required
The original comparator is placebo or control management.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Comparator, shared treatment, lifestyle management and differences between arms
Material needed: Original-trial comparator/shared-management tables. This records needed materials; no new research was executed.
9 Unverified Full text not readStored summary read N09 · Evidence conditionHow are changes in diet, exercise and medicines distinguished from curcumin?Required
The original explanation describes diverse products, populations and accompanying lifestyle measures.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Diet/exercise, weight-management/metabolic medicines, cointerventions and changes
Material needed: Trial-specific concomitant-treatment, lifestyle and metabolic-medicine records. This records needed materials; no new research was executed.
10 Partly verified Full text not readStored summary read N10 · Evidence conditionIs body weight in kg the same outcome as BMI, waist circumference or body fat?Required
The original principal endpoint is body-weight change in kg. The supplementary explanation keeps BMI, waist circumference and body fat separate.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Separating weight change in kg from other anthropometric endpoints
Material needed: Endpoint-specific definitions, units and extracted results. This records needed materials; no new research was executed.
11 Partly verified Full text not readStored summary read N11 · Evidence conditionWhat are the overall weight estimate and interval?Required
The retained overall body-weight result is MD −0.59 kg, 95% CI −0.81 to −0.36.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Body-weight MD in kg, 95% CI, contributing trials/denominators and measurement timepoints
Material needed: Body-weight forest plot, extraction table, denominators/timepoints and analysis methods. This records needed materials; no new research was executed.
12 Partly verified Full text not readStored summary read N12 · Evidence conditionWhat is the scope of the enhanced-formulation −0.80 kg result?Required
The original result also records enhanced formulations at −0.80 kg, interval −1.38 to −0.23; the reader answer also describes 0.80 kg.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Enhanced-formulation classification, contributing counts, MD, interval, population/dose/duration
Material needed: Enhanced-formulation classification, subgroup forest plot, denominators and analysis plan. This records needed materials; no new research was executed.
13 Unverified Full text not readStored summary read N13 · Evidence conditionIs this direct evidence that enhanced formulations outperform conventional forms?Required
The original records the overall pooled value and enhanced-formulation subgroup value, without a direct between-formulation comparison estimate.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Direct randomized comparisons between formulations, interaction tests and shared population/dose conditions
Material needed: Direct formulation-comparison studies and subgroup comparison plans/tests. This records needed materials; no new research was executed.
14 Unverified Full text not readStored summary read N14 · Evidence conditionWhat can this table establish about BMI?Required
The original supplementary explanation keeps BMI separate from the weight-in-kg verdict.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
BMI units, measurement timepoints, contributing trials and effects/intervals
Material needed: Separate BMI results/forest plot and definitions. This records needed materials; no new research was executed.
15 Unverified Full text not readStored summary read N15 · Evidence conditionHow is waist circumference retained as a separate outcome?Required
The original supplementary explanation separates waist circumference from the weight-in-kg verdict.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Waist-circumference units, measurement sites, timepoints and effects/intervals
Material needed: Separate waist-circumference definitions/results and contribution lists. This records needed materials; no new research was executed.
16 Unverified Full text not readStored summary read N16 · Evidence conditionCan the weight estimate stand in for body-fat reduction?Required
The original supplementary explanation keeps body fat separate from body weight in kg.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Body-fat measurement methods, units, denominators, timepoints and effects
Material needed: Separate body-fat measurement/effect tables. This records needed materials; no new research was executed.
17 Partly verified Full text not readStored summary read N17 · Evidence conditionWhat counts are the 14 meta-analyses and 50 RCTs?Required
The original research description refers to 14 existing meta-analyses and an updated search identifying 50 RCTs with weight-in-kg results. The evidence sample description is 50 RCTs; 21 at high risk.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Separating umbrella reviews, updated RCTs and endpoint-specific contributions
Material needed: Lists of the 14 reviews/50 trials, overlap relationships and endpoint contributions. This records needed materials; no new research was executed.
18 Unverified Full text not readStored summary read N18 · Evidence conditionHow many participants were randomized, analyzed and completed across 50 trials?Required
The current sample description records only 50 trials and 21 at high risk.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Overall/trial-specific randomized, analyzed, completed and endpoint/subgroup denominators
Material needed: Original-trial flow, denominators and meta-analysis contributing-participant tables. This records needed materials; no new research was executed.
19 Unverified Full text not readStored summary read N19 · Evidence conditionDid the same trial recur across reviews and papers?Required
The source retains 1 umbrella-review/updated-meta-analysis report.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Original-trial IDs, multiple reports, follow-up/registration and review inclusion relationships
Material needed: Relationships among included trials, reports and registrations. This records needed materials; no new research was executed.
20 Unverified Full text not readStored summary read N20 · Evidence conditionWhen and how far did the updated search extend?Required
The original mentions an umbrella review and updated searching.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Search date, databases, strategies, registration/unpublished material and formulation/population eligibility
Material needed: Meta-analysis search strategies, eligibility, selection flow and search dates. This records needed materials; no new research was executed.
21 Unverified Full text not readStored summary read N21 · Evidence conditionWhich original-trial weight values were extracted, and how?Required
The retained use conditions describe body-weight change in kg; the evidence records body weight in kg and pooled MD.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Final/change values, kg units, multiple timepoints, multiple arms, adjustment and duplicate selection
Material needed: Body-weight extraction, original result tables and analysis-code explanation. This records needed materials; no new research was executed.
22 Unverified Full text not readStored summary read N22 · Evidence conditionHow were MD and between-study heterogeneity estimated?Required
The original result records MD and intervals; its explanation describes diversity in products, populations and lifestyles.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Pooling model, weights, heterogeneity, prediction intervals and subgroups
Material needed: Statistical methods, forest plot, heterogeneity/prediction intervals and subgroup plans. This records needed materials; no new research was executed.
23 Partly verified Full text not readStored summary read N23 · Evidence conditionWhat are the 21 high-risk trials and original 42% description?Required
The evidence sample description records 21 trials at high risk of bias; the key-point description refers to 21 trials, and the grade rationale describes 42% of original trials as high risk.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Trial-specific risk assessment, tools/domains and contribution weights
Material needed: Original risk-assessment tables, tools and endpoint links. This records needed materials; no new research was executed.
24 Unverified Full text not readStored summary read N24 · Evidence conditionWhat were trial-specific randomization, masking and effects of interest?Required
The original design is described as a meta-analysis of RCTs.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Trial-specific allocation/concealment, masking, effects of interest and baseline balance
Material needed: Original-trial methods and allocation/analysis tables. This records needed materials; no new research was executed.
25 Unverified Full text not readStored summary read N25 · Evidence conditionHow were attrition, nonadherence and missing weight measurements handled?Required
The current summary does not contain trial-specific attrition, adherence or missing-data information.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Arm-specific attrition, adherence, missing-data handling and weight-analysis denominators
Material needed: Original-trial flow, adherence and missing-data/sensitivity tables. This records needed materials; no new research was executed.
26 Unverified Full text not readStored summary read N26 · Evidence conditionWhat are the results for high-risk/small trials and publication bias?Required
The source describes 21 high-risk trials alongside a small pooled effect.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
High-risk exclusions, small studies, missing/publication bias and influence analyses
Material needed: Sensitivity/influence, missing-report and publication-bias material. This records needed materials; no new research was executed.
27 Unverified Full text not readStored summary read N27 · Evidence conditionDo PROSPERO plans correspond to weight/subgroup analyses?Required
The retained design describes a preregistered umbrella review/meta-analysis; funding/bibliography record PROSPERO CRD42022321112.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Registration content, dated plans, body weight/BMI/waist/enhanced formulations and amendments
Material needed: PROSPERO content/history, plans and analysis lists. This records needed materials; no new research was executed.
28 Partly verified Full text not readStored summary read N28 · Evidence conditionAre the statistical signal and clinical meaning of 0.59 kg the same?Required
The original reader answer describes a statistical signal without large weight loss. Its key-point description states that the mean is below 1 kg, and the grade rationale says it falls below a clinical threshold.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Effects/intervals, original interpretation, patient importance, baseline weight and persistence
Material needed: Prespecified clinical importance, baseline/maintenance and patient-important outcomes. This records needed materials; no new research was executed.
29 Partly verified Full text not readStored summary read N29 · Evidence conditionWhat is retained here from the original independence narrative?Required
The original counterview describes recurring reduction directions across independent trials/umbrella review. The original R2/I2 axes are retained.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Unique trials/teams, question/formulation correspondence and overlap among meta-analyses
Material needed: Original-trial families, teams/support relationships and exact formulation/endpoint lists. This records needed materials; no new research was executed.
30 Partly verified Full text not readStored summary read N30 · Evidence conditionAre PMID, DOI, PROSPERO and the stored summary distinguished?Required
The original citation is Unhapipatpong et al., Am J Clin Nutr.2023;117:1005-1016, PMID36898635, DOI10.1016/j.ajcnut.2023.03.006, PROSPERO CRD42022321112. The material read is the stored JSON.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Original-report bibliography, registration wording, external-unread scope and stored JSON
Material needed: Articles, registration and supplementary/original-trial material corresponding to the citation. This records needed materials; no new research was executed.
31 Unverified Full text not readStored summary read N31 · Evidence conditionWhat are the nongovernmental support and product/author roles?Required
The retained funding description records nongovernmental research support; PROSPERO CRD42022321112.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Cash/product support, affiliations/conflicts and meta-analysis/original-trial roles
Material needed: Original meta-analysis/trial funding, conflict, author and product-support disclosures. This records needed materials; no new research was executed.
32 Partly verified Full text not readStored summary read N32 · Evidence conditionHow do original dates differ from the preparation timestamp?Required
The original evidence date is 2026-09-08; the English correction is dated 2026-09-14. The meta-analysis bibliography is dated 2023.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Original evidence date, correction date, meta-analysis publication/search and preparation timestamp
Material needed: Original search, receipt, publication and amendment-event records. This records needed materials; no new research was executed.
33 Partly verified Full text not readStored summary read N33 · Evidence conditionHow are generic English wording and the 1-field correction retained?Required
The English reader answer records 0.59/0.80 kg. Generic explanations remain in English sample, funding, endpoint, result and evidence-weight fields; the correction describes changing 1 field.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Korean/English results, generic English evidence wording and before/after correction records
Material needed: Complete before/after English-correction originals and result translation. This records needed materials; no new research was executed.
34 Partly verified Full text not readStored summary read N34 · Evidence conditionWhat is the role of C54, historical cross-checking and axes here?Required
The original C54/Caution, B/S/R2/I2/E~/B2/C0 axes and historical independent Codex cross-check wording are preserved in the source.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Original grade, score, safety, axes, grade decision and empty values
Material needed: The original verdict and subsequent authorized correction events. This records needed materials; no new research was executed.
35 Partly verified Full text not readStored summary read N35 · Evidence conditionFor which events and denominators were gastrointestinal complaints reported?Required
The retained safety wording describes gastrointestinal complaints as the main issue in short trials.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Event definitions/collection, arm-specific events/denominators, discontinuation/missingness and duration
Material needed: Original-trial adverse events/discontinuations, collection and arm-specific harm tables. This records needed materials; no new research was executed.
36 Partly verified Full text not readStored summary read N36 · Evidence conditionWhat is known about formulation-specific safety beyond short-term use?Supplementary; required when extending safety scope
The original safety wording states that long-term/high-dose safety and medicine interactions are not adequately established by formulation.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Longer-term/high-dose use, formulation/absorption, vulnerable groups and medicine interactions
Material needed: Longer follow-up, formulation/dose-specific harms and interaction material. This records needed materials; no new research was executed.
37 Unverified Full text not readStored summary read N37 · Evidence conditionAre harm timing, comparisons, alternative causes and independent cases available?Supplementary; required for harm causality/replication scope
The current manuscript retains only general short-term gastrointestinal/long-term interaction precautions.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Onset/recovery, discontinuation/re-exposure, comparator/concomitant medicines and case families
Material needed: Individual-event timing, concomitant/alternative explanations, between-group harms and unique-case material. This records needed materials; no new research was executed.
38 Unverified Full text not readStored summary read N38 · Evidence conditionDoes enhanced bioavailability cause the weight effect?Supplementary; required for mechanism/formulation-superiority claims
The source records the enhanced-formulation weight subgroup value and warns against product interchangeability.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Formulation-specific exposure/absorption, direct weight comparisons and alternative explanations
Material needed: Formulation-specific exposure/absorption and direct clinical outcomes. This records needed materials; no new research was executed.
39 Partly verified Full text not readStored summary read N39 · Evidence conditionHow are the stored summary and unread materials connected?Required
The full stored JSON was read for preparation, with the original PubMed citation URL retained. External material remains unread, with no access attempt.
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Material-specific acquisition/reading, original citation links and condition/evidence-change events
Material needed: Original material/corrections supplied or separately authorized. This records needed materials; no new research was executed.
No items match your search or filter.

39 itemsWhat the statuses mean

Assessment scope

Stored-material review date
Not recorded
Original evidence cut-off
2026-09-08
Scope actually checked
Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean
The 2026-09-08 date recorded for materials is the original evidence date, not an external-reading date. Authorship timestamps on 2026-10-06 are preparation records, not completed-content-review/external-verification dates. Actual review/verification dates remain unrecorded.
Population
The retained scope is adults with overweight, obesity or obesity-related metabolic disease. Original-trial eligibility, diseases, baseline BMI/weight, population contributions and direct effects remain unverified.
Ingredient, formulation and route
The evidence mixes conventional and bioavailability-enhanced oral curcumin/curcuminoid formulations. Piperine combinations and other products, carriers and routes remain distinct; products, content, classifications, contributions and direct effects remain unverified.
Dose
The original record describes varied trial-specific doses without an established single optimum. Actual mg/day, frequency, active amounts, adherence and direct dose response remain unverified; individual recommended doses are not assigned.
Comparator
The retained comparator is placebo or control management. Product-specific placebo, lifestyle measures, concomitant obesity/metabolic treatment, shared care and medicine changes remain incompletely verified; combined effects are not assigned to curcumin alone.
Measured outcome
The selected endpoint is body-weight change in kg. BMI, waist circumference and body fat remain distinct; change/final-value definitions, measurement, denominators, timepoints and importance remain separately unverified. Results are not converted into other endpoints or individual percentage weight loss.
Duration
The record describes weeks to months across original trials. Duration distributions, actual weight-measurement/extraction timepoints, longer-term maintenance and persistence after discontinuation remain unverified.
Questions outside this scope
The selected question concerns mixed oral curcumin formulations and body weight in kg in adults with overweight, obesity or related metabolic disease. Individual products, piperine combinations, other routes, BMI/waist/body fat and obesity-treatment replacement are different direct questions.; The original C/54/Caution and B/S/R2/I2/E~/B2/C0 are retained. Historical independence/cross-checking and generic English verification wording are not inherited as current original-source reading, formal assessment or independent clinical validation.; The overall MD −0.59 kg, 95% CI −0.81 to −0.36 is retained. A pooled mean does not establish guaranteed loss for every product/person or a prediction interval for individual products/future trials.; The enhanced-formulation −0.80 kg and interval −1.38 to −0.23 are subgroup records. Confidence-level details, contributing denominators and direct formulation comparisons remain unverified; subtraction from the overall estimate does not generate additional loss or superiority.; The 14 reviews, 50 RCTs, 21 high-risk trials and 42% are original descriptions. Overlap among reviews, reports, trials, participants and teams remains distinct; unique counts, independent replication and proportions are not newly added or recalculated.; PROSPERO CRD42022321112 and the preregistration/nongovernmental-support descriptions are retained without promotion to actual registration/plan reading or verified funders, product support, employee authorship, conflicts or independence.; The original mean below 1 kg and below-clinical-threshold interpretation are retained. Threshold definitions, patient importance, weight-loss maintenance and long-term/high-dose/formulation-specific harms remain unverified; new clinical thresholds, percentage loss, optimum doses and overall safety are not established.; The original evidence date 2026-09-08, correction of 1 English field on 2026-09-14 and authorship date 2026-10-06 remain distinct. Authorship timestamps and dated stored notes are not actual external-reading/completed-content-review dates; review dates remain unrecorded.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · 2023 · Curcumin and body weight: umbrella review and updated meta-analysis

PubMed

Material type
Stored description of a preregistered umbrella review/updated RCT meta-analysis; actual registration, inclusion tables and methods remain externally unverified
Materials actually read
Stored summary read; external abstracts/full texts, registration and original trials unread, with no access attempt
Findings recorded in the stored summary
MD −0.59 kg, 95% CI −0.81 to −0.36; enhanced formulations −0.80 kg, interval −1.38 to −0.23
Record level
These are overall pooled weight and enhanced-formulation subgroup values. Weight/BMI/waist/body fat, reviews/trials/participants and contributing denominators remain distinct; original articles, registration, analyses, support and harm material remain unread.
Study overlap and independent replication
The stored umbrella-review/updated report remains distinct from original trials, reviews, reports and participants. Overlap, unique trials/participants and team independence remain unverified; the original independence narrative is not converted into new counts or certification.
Public availability, access and reading status by material
MaterialPublic availabilityAccess statusActually readNotes
Stored meta-analysis summaryExisting stored summary acquiredStored summaryStored summary readOnly the stored summary was read for preparation. This is not actual acquisition/reading of the meta-analysis full text/original trials or clinical validation. Only the stored summary/original bibliography was read. External abstracts, full texts, PROSPERO, inclusion tables, original-trial, extraction, analysis, harm and support material remain unread. URLs, identifiers and original narratives alone do not certify existence/public availability, acquisition, reading, prespecification, independence or fulfilled conditions. The 2026-09-08 date recorded for materials is the original evidence date, not an external-reading date. Authorship timestamps on 2026-10-06 are preparation records, not completed-content-review/external-verification dates. Actual review/verification dates remain unrecorded.
External article identity link · Original PubMed citationOriginal bibliography link only; external content unreadUnread; no access attemptUnreadPMID36898635, DOI10.1016/j.ajcnut.2023.03.006 and the original PubMed link are stored identifiers. Successful access, acquisition and actual reading of the page/abstract were not verified. Only the stored summary/original bibliography was read. External abstracts, full texts, PROSPERO, inclusion tables, original-trial, extraction, analysis, harm and support material remain unread. URLs, identifiers and original narratives alone do not certify existence/public availability, acquisition, reading, prespecification, independence or fulfilled conditions. The 2026-09-08 date recorded for materials is the original evidence date, not an external-reading date. Authorship timestamps on 2026-10-06 are preparation records, not completed-content-review/external-verification dates. Actual review/verification dates remain unrecorded.
External full text · Umbrella review/updated meta-analysisOriginal bibliography link only; external content unreadUnread; no access attemptUnreadA bibliographic link is not promoted to full-text public availability, acquisition or reading. Original analyses, methods and supplements remain unread. Only the stored summary/original bibliography was read. External abstracts, full texts, PROSPERO, inclusion tables, original-trial, extraction, analysis, harm and support material remain unread. URLs, identifiers and original narratives alone do not certify existence/public availability, acquisition, reading, prespecification, independence or fulfilled conditions. The 2026-09-08 date recorded for materials is the original evidence date, not an external-reading date. Authorship timestamps on 2026-10-06 are preparation records, not completed-content-review/external-verification dates. Actual review/verification dates remain unrecorded.
Registration material · PROSPERO CRD42022321112Needed material; existence and public availability unverifiedUnread; no access attemptUnreadPROSPERO CRD42022321112 is the retained registration identifier. Registration content, timing, amendments and weight/subgroup correspondence remain unread; prospective registration of individual trials is not certified. Only the stored summary/original bibliography was read. External abstracts, full texts, PROSPERO, inclusion tables, original-trial, extraction, analysis, harm and support material remain unread. URLs, identifiers and original narratives alone do not certify existence/public availability, acquisition, reading, prespecification, independence or fulfilled conditions. The 2026-09-08 date recorded for materials is the original evidence date, not an external-reading date. Authorship timestamps on 2026-10-06 are preparation records, not completed-content-review/external-verification dates. Actual review/verification dates remain unrecorded.
Review/trial/report-family contributions · 14 reviews/50 trialsNeeded material; existence and public availability unverifiedUnread; no access attemptUnreadInclusion, overlap, report families and endpoint contributions of the 14 reviews/50 trials remain unverified. Participant, unique-trial and independent-team totals are not newly generated. Only the stored summary/original bibliography was read. External abstracts, full texts, PROSPERO, inclusion tables, original-trial, extraction, analysis, harm and support material remain unread. URLs, identifiers and original narratives alone do not certify existence/public availability, acquisition, reading, prespecification, independence or fulfilled conditions. The 2026-09-08 date recorded for materials is the original evidence date, not an external-reading date. Authorship timestamps on 2026-10-06 are preparation records, not completed-content-review/external-verification dates. Actual review/verification dates remain unrecorded.
Endpoint extraction/denominators/results · Weight/enhanced formulations/BMI/waist/body fatNeeded material; existence and public availability unverifiedUnread; no access attemptUnreadActual extraction, denominators, timepoints and results for weight, enhanced formulations, BMI, waist and body fat remain unverified. The confidence level of the enhanced-formulation interval is not assumed, and other endpoints are not substituted. Only the stored summary/original bibliography was read. External abstracts, full texts, PROSPERO, inclusion tables, original-trial, extraction, analysis, harm and support material remain unread. URLs, identifiers and original narratives alone do not certify existence/public availability, acquisition, reading, prespecification, independence or fulfilled conditions. The 2026-09-08 date recorded for materials is the original evidence date, not an external-reading date. Authorship timestamps on 2026-10-06 are preparation records, not completed-content-review/external-verification dates. Actual review/verification dates remain unrecorded.
Pooling methods, risk assessment, sensitivity and missing/publication biasNeeded material; existence and public availability unverifiedUnread; no access attemptUnreadThe 21 high-risk trials and 42% are original descriptions. Risk tables/tools, weights, heterogeneity, sensitivity and missing/publication bias remain unverified; no recalculation or formal-method execution was performed. Only the stored summary/original bibliography was read. External abstracts, full texts, PROSPERO, inclusion tables, original-trial, extraction, analysis, harm and support material remain unread. URLs, identifiers and original narratives alone do not certify existence/public availability, acquisition, reading, prespecification, independence or fulfilled conditions. The 2026-09-08 date recorded for materials is the original evidence date, not an external-reading date. Authorship timestamps on 2026-10-06 are preparation records, not completed-content-review/external-verification dates. Actual review/verification dates remain unrecorded.
Products, formulations, doses, populations, duration and lifestyle/concomitant careNeeded material; existence and public availability unverifiedUnread; no access attemptUnreadProducts, contents, carriers, doses, populations, durations and both arms’ lifestyle/concomitant medicines remain incompletely verified. Piperine/lifestyle combination effects are not assigned to curcumin alone. Only the stored summary/original bibliography was read. External abstracts, full texts, PROSPERO, inclusion tables, original-trial, extraction, analysis, harm and support material remain unread. URLs, identifiers and original narratives alone do not certify existence/public availability, acquisition, reading, prespecification, independence or fulfilled conditions. The 2026-09-08 date recorded for materials is the original evidence date, not an external-reading date. Authorship timestamps on 2026-10-06 are preparation records, not completed-content-review/external-verification dates. Actual review/verification dates remain unrecorded.
Harms, discontinuation, long-term/high-dose use and formulation-specific interactionsNeeded material; existence and public availability unverifiedUnread; no access attemptUnreadOriginal gastrointestinal, long-term/high-dose and interaction precautions are retained. Actual event definitions, collection, arm-specific harms, denominators, causality and rare harms remain unverified; absence of events and overall safety are not established. Only the stored summary/original bibliography was read. External abstracts, full texts, PROSPERO, inclusion tables, original-trial, extraction, analysis, harm and support material remain unread. URLs, identifiers and original narratives alone do not certify existence/public availability, acquisition, reading, prespecification, independence or fulfilled conditions. The 2026-09-08 date recorded for materials is the original evidence date, not an external-reading date. Authorship timestamps on 2026-10-06 are preparation records, not completed-content-review/external-verification dates. Actual review/verification dates remain unrecorded.
Original funding, conflict and product-support disclosuresNeeded material; existence and public availability unverifiedUnread; no access attemptUnreadNongovernmental support remains distinct from the PROSPERO identifier. Original meta-analysis/trial funder, product-support, employee-authorship, role and conflict disclosures remain unread; independence and noninvolvement are not certified. Only the stored summary/original bibliography was read. External abstracts, full texts, PROSPERO, inclusion tables, original-trial, extraction, analysis, harm and support material remain unread. URLs, identifiers and original narratives alone do not certify existence/public availability, acquisition, reading, prespecification, independence or fulfilled conditions. The 2026-09-08 date recorded for materials is the original evidence date, not an external-reading date. Authorship timestamps on 2026-10-06 are preparation records, not completed-content-review/external-verification dates. Actual review/verification dates remain unrecorded.

Report counts versus independent study counts

The stored umbrella-review/updated report remains distinct from original trials, reviews, reports and participants. Overlap, unique trials/participants and team independence remain unverified; the original independence narrative is not converted into new counts or certification.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which curcumin preparation and body-weight question are addressed?
Required materials and conditions
Oral curcumin, population, body weight in kg, comparison and weeks-to-months scope
Conditions for verification
Original records on Oral curcumin, population, body weight in kg, comparison and weeks-to-months scope must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Oral curcumin, population, body weight in kg, comparison and weeks-to-months scope is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N02 · What are the conventional and bioavailability-enhanced formulations?
Required materials and conditions
Curcuma longa-derived curcumin/curcuminoids and oral-formulation classification
Conditions for verification
Original records on Curcuma longa-derived curcumin/curcuminoids and oral-formulation classification must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Curcuma longa-derived curcumin/curcuminoids and oral-formulation classification is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N03 · How are piperine, diet and exercise combination effects distinguished?
Required materials and conditions
Separating curcumin alone from absorption-enhancer/lifestyle combinations
Conditions for verification
Original records on Separating curcumin alone from absorption-enhancer/lifestyle combinations must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Separating curcumin alone from absorption-enhancer/lifestyle combinations is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N04 · Are oral supplementation, turmeric and topical oral products the same intervention?
Required materials and conditions
Distinguishing swallowed supplements from conventional turmeric, topical products and special formulations
Conditions for verification
Original records on Distinguishing swallowed supplements from conventional turmeric, topical products and special formulations must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Distinguishing swallowed supplements from conventional turmeric, topical products and special formulations is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N05 · Were overweight, obesity and metabolic-disease populations distinguished?
Required materials and conditions
Trial-specific weight status, obesity-related metabolic disease and baseline BMI/body weight
Conditions for verification
Original records on Trial-specific weight status, obesity-related metabolic disease and baseline BMI/body weight must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Trial-specific weight status, obesity-related metabolic disease and baseline BMI/body weight is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N06 · What doses were used, and is an optimum established?
Required materials and conditions
Trial-specific administered doses, constituent content, frequency and adherence
Conditions for verification
Original records on Trial-specific administered doses, constituent content, frequency and adherence must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Trial-specific administered doses, constituent content, frequency and adherence is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N07 · Which weight results across weeks to months were pooled?
Required materials and conditions
Trial-specific treatment duration, measurement visits and end/follow-up timepoints
Conditions for verification
Original records on Trial-specific treatment duration, measurement visits and end/follow-up timepoints must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Trial-specific treatment duration, measurement visits and end/follow-up timepoints is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N08 · What did placebo or control management involve?
Required materials and conditions
Comparator, shared treatment, lifestyle management and differences between arms
Conditions for verification
Original records on Comparator, shared treatment, lifestyle management and differences between arms must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Comparator, shared treatment, lifestyle management and differences between arms is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N09 · How are changes in diet, exercise and medicines distinguished from curcumin?
Required materials and conditions
Diet/exercise, weight-management/metabolic medicines, cointerventions and changes
Conditions for verification
Original records on Diet/exercise, weight-management/metabolic medicines, cointerventions and changes must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Diet/exercise, weight-management/metabolic medicines, cointerventions and changes is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N10 · Is body weight in kg the same outcome as BMI, waist circumference or body fat?
Required materials and conditions
Separating weight change in kg from other anthropometric endpoints
Conditions for verification
Original records on Separating weight change in kg from other anthropometric endpoints must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Separating weight change in kg from other anthropometric endpoints is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N11 · What are the overall weight estimate and interval?
Required materials and conditions
Body-weight MD in kg, 95% CI, contributing trials/denominators and measurement timepoints
Conditions for verification
Original records on Body-weight MD in kg, 95% CI, contributing trials/denominators and measurement timepoints must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Body-weight MD in kg, 95% CI, contributing trials/denominators and measurement timepoints is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N12 · What is the scope of the enhanced-formulation −0.80 kg result?
Required materials and conditions
Enhanced-formulation classification, contributing counts, MD, interval, population/dose/duration
Conditions for verification
Original records on Enhanced-formulation classification, contributing counts, MD, interval, population/dose/duration must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Enhanced-formulation classification, contributing counts, MD, interval, population/dose/duration is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N13 · Is this direct evidence that enhanced formulations outperform conventional forms?
Required materials and conditions
Direct randomized comparisons between formulations, interaction tests and shared population/dose conditions
Conditions for verification
Original records on Direct randomized comparisons between formulations, interaction tests and shared population/dose conditions must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Direct randomized comparisons between formulations, interaction tests and shared population/dose conditions is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N14 · What can this table establish about BMI?
Required materials and conditions
BMI units, measurement timepoints, contributing trials and effects/intervals
Conditions for verification
Original records on BMI units, measurement timepoints, contributing trials and effects/intervals must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on BMI units, measurement timepoints, contributing trials and effects/intervals is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N15 · How is waist circumference retained as a separate outcome?
Required materials and conditions
Waist-circumference units, measurement sites, timepoints and effects/intervals
Conditions for verification
Original records on Waist-circumference units, measurement sites, timepoints and effects/intervals must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Waist-circumference units, measurement sites, timepoints and effects/intervals is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N16 · Can the weight estimate stand in for body-fat reduction?
Required materials and conditions
Body-fat measurement methods, units, denominators, timepoints and effects
Conditions for verification
Original records on Body-fat measurement methods, units, denominators, timepoints and effects must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Body-fat measurement methods, units, denominators, timepoints and effects is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N17 · What counts are the 14 meta-analyses and 50 RCTs?
Required materials and conditions
Separating umbrella reviews, updated RCTs and endpoint-specific contributions
Conditions for verification
Original records on Separating umbrella reviews, updated RCTs and endpoint-specific contributions must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Separating umbrella reviews, updated RCTs and endpoint-specific contributions is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N18 · How many participants were randomized, analyzed and completed across 50 trials?
Required materials and conditions
Overall/trial-specific randomized, analyzed, completed and endpoint/subgroup denominators
Conditions for verification
Original records on Overall/trial-specific randomized, analyzed, completed and endpoint/subgroup denominators must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Overall/trial-specific randomized, analyzed, completed and endpoint/subgroup denominators is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N19 · Did the same trial recur across reviews and papers?
Required materials and conditions
Original-trial IDs, multiple reports, follow-up/registration and review inclusion relationships
Conditions for verification
Original records on Original-trial IDs, multiple reports, follow-up/registration and review inclusion relationships must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Original-trial IDs, multiple reports, follow-up/registration and review inclusion relationships is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N20 · When and how far did the updated search extend?
Required materials and conditions
Search date, databases, strategies, registration/unpublished material and formulation/population eligibility
Conditions for verification
Original records on Search date, databases, strategies, registration/unpublished material and formulation/population eligibility must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Search date, databases, strategies, registration/unpublished material and formulation/population eligibility is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N21 · Which original-trial weight values were extracted, and how?
Required materials and conditions
Final/change values, kg units, multiple timepoints, multiple arms, adjustment and duplicate selection
Conditions for verification
Original records on Final/change values, kg units, multiple timepoints, multiple arms, adjustment and duplicate selection must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Final/change values, kg units, multiple timepoints, multiple arms, adjustment and duplicate selection is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N22 · How were MD and between-study heterogeneity estimated?
Required materials and conditions
Pooling model, weights, heterogeneity, prediction intervals and subgroups
Conditions for verification
Original records on Pooling model, weights, heterogeneity, prediction intervals and subgroups must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Pooling model, weights, heterogeneity, prediction intervals and subgroups is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N23 · What are the 21 high-risk trials and original 42% description?
Required materials and conditions
Trial-specific risk assessment, tools/domains and contribution weights
Conditions for verification
Original records on Trial-specific risk assessment, tools/domains and contribution weights must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Trial-specific risk assessment, tools/domains and contribution weights is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N24 · What were trial-specific randomization, masking and effects of interest?
Required materials and conditions
Trial-specific allocation/concealment, masking, effects of interest and baseline balance
Conditions for verification
Original records on Trial-specific allocation/concealment, masking, effects of interest and baseline balance must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Trial-specific allocation/concealment, masking, effects of interest and baseline balance is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N25 · How were attrition, nonadherence and missing weight measurements handled?
Required materials and conditions
Arm-specific attrition, adherence, missing-data handling and weight-analysis denominators
Conditions for verification
Original records on Arm-specific attrition, adherence, missing-data handling and weight-analysis denominators must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Arm-specific attrition, adherence, missing-data handling and weight-analysis denominators is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N26 · What are the results for high-risk/small trials and publication bias?
Required materials and conditions
High-risk exclusions, small studies, missing/publication bias and influence analyses
Conditions for verification
Original records on High-risk exclusions, small studies, missing/publication bias and influence analyses must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on High-risk exclusions, small studies, missing/publication bias and influence analyses is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N27 · Do PROSPERO plans correspond to weight/subgroup analyses?
Required materials and conditions
Registration content, dated plans, body weight/BMI/waist/enhanced formulations and amendments
Conditions for verification
Original records on Registration content, dated plans, body weight/BMI/waist/enhanced formulations and amendments must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Registration content, dated plans, body weight/BMI/waist/enhanced formulations and amendments is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N28 · Are the statistical signal and clinical meaning of 0.59 kg the same?
Required materials and conditions
Effects/intervals, original interpretation, patient importance, baseline weight and persistence
Conditions for verification
Original records on Effects/intervals, original interpretation, patient importance, baseline weight and persistence must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Effects/intervals, original interpretation, patient importance, baseline weight and persistence is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N29 · What is retained here from the original independence narrative?
Required materials and conditions
Unique trials/teams, question/formulation correspondence and overlap among meta-analyses
Conditions for verification
Original records on Unique trials/teams, question/formulation correspondence and overlap among meta-analyses must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Unique trials/teams, question/formulation correspondence and overlap among meta-analyses is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N30 · Are PMID, DOI, PROSPERO and the stored summary distinguished?
Required materials and conditions
Original-report bibliography, registration wording, external-unread scope and stored JSON
Conditions for verification
Original records on Original-report bibliography, registration wording, external-unread scope and stored JSON must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Original-report bibliography, registration wording, external-unread scope and stored JSON is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N31 · What are the nongovernmental support and product/author roles?
Required materials and conditions
Cash/product support, affiliations/conflicts and meta-analysis/original-trial roles
Conditions for verification
Original records on Cash/product support, affiliations/conflicts and meta-analysis/original-trial roles must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Cash/product support, affiliations/conflicts and meta-analysis/original-trial roles is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N32 · How do original dates differ from the preparation timestamp?
Required materials and conditions
Original evidence date, correction date, meta-analysis publication/search and preparation timestamp
Conditions for verification
Original records on Original evidence date, correction date, meta-analysis publication/search and preparation timestamp must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Original evidence date, correction date, meta-analysis publication/search and preparation timestamp is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N33 · How are generic English wording and the 1-field correction retained?
Required materials and conditions
Korean/English results, generic English evidence wording and before/after correction records
Conditions for verification
Original records on Korean/English results, generic English evidence wording and before/after correction records must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Korean/English results, generic English evidence wording and before/after correction records is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N34 · What is the role of C54, historical cross-checking and axes here?
Required materials and conditions
Original grade, score, safety, axes, grade decision and empty values
Conditions for verification
Original records on Original grade, score, safety, axes, grade decision and empty values must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Original grade, score, safety, axes, grade decision and empty values is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N35 · For which events and denominators were gastrointestinal complaints reported?
Required materials and conditions
Event definitions/collection, arm-specific events/denominators, discontinuation/missingness and duration
Conditions for verification
Original records on Event definitions/collection, arm-specific events/denominators, discontinuation/missingness and duration must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Event definitions/collection, arm-specific events/denominators, discontinuation/missingness and duration is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N36 · What is known about formulation-specific safety beyond short-term use?
Required materials and conditions
Longer-term/high-dose use, formulation/absorption, vulnerable groups and medicine interactions
Conditions for verification
Original records on Longer-term/high-dose use, formulation/absorption, vulnerable groups and medicine interactions must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Supplementary; required when extending safety scope
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Longer-term/high-dose use, formulation/absorption, vulnerable groups and medicine interactions is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N37 · Are harm timing, comparisons, alternative causes and independent cases available?
Required materials and conditions
Onset/recovery, discontinuation/re-exposure, comparator/concomitant medicines and case families
Conditions for verification
Original records on Onset/recovery, discontinuation/re-exposure, comparator/concomitant medicines and case families must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Supplementary; required for harm causality/replication scope
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Onset/recovery, discontinuation/re-exposure, comparator/concomitant medicines and case families is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N38 · Does enhanced bioavailability cause the weight effect?
Required materials and conditions
Formulation-specific exposure/absorption, direct weight comparisons and alternative explanations
Conditions for verification
Original records on Formulation-specific exposure/absorption, direct weight comparisons and alternative explanations must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Supplementary; required for mechanism/formulation-superiority claims
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Formulation-specific exposure/absorption, direct weight comparisons and alternative explanations is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
N39 · How are the stored summary and unread materials connected?
Required materials and conditions
Material-specific acquisition/reading, original citation links and condition/evidence-change events
Conditions for verification
Original records on Material-specific acquisition/reading, original citation links and condition/evidence-change events must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability
Required
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Why this condition is needed
Material on Material-specific acquisition/reading, original citation links and condition/evidence-change events is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.
Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle
Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review
Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle
Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review
Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle
Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review
Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle
Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review
Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle
Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review
Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.
What the statuses mean
Partly verified
Partial information from the stored summary is linked; detailed originals and content review remain incomplete.
Unverified
Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.
Review incomplete
Review of existing content remains incomplete.
Met
This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.
Not reported
Unreported within material actually read. Unread external material is not relabeled as unreported.
Inaccessible
This means actual access failure. External access was not attempted in this work, so this state was not assigned.
Not applicable
Used only with an application exception and reason based on the question scope.
Conflicting data
This requires actual comparison of materials; no new conflict judgment was made in this work.
Insufficient evidence for the conditions
This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade.

Change history

2026-10-24 · Public page/material version 1.0

The public view and materials were prepared from the existing 39 items. No new clinical search, verification-state change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-09-08) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which curcumin preparation and body-weight question are addressed?

Current findings
The original claim concerns reduced body weight in kg in adults with overweight or obesity. The retained meta-analysis summary mixes conventional and enhanced formulations.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Review of the independent-claim boundary remains incomplete, and subsidiary-claim records are empty.
Required materials and conditions
Oral curcumin, population, body weight in kg, comparison and weeks-to-months scope
Materials to obtain first
Meta-analysis eligibility/question definitions and original-trial lists
Further research
Material needed: Meta-analysis eligibility/question definitions and original-trial lists. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Oral curcumin, population, body weight in kg, comparison and weeks-to-months scope must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Oral curcumin, population, body weight in kg, comparison and weeks-to-months scope is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N02 · What are the conventional and bioavailability-enhanced formulations?

Current findings
The retained use conditions describe conventional and bioavailability-enhanced oral formulations, with piperine combinations kept separate.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Individual product names, curcuminoid contents, nano/micellar/phytosome classifications and actual included formulations remain unverified.
Required materials and conditions
Curcuma longa-derived curcumin/curcuminoids and oral-formulation classification
Materials to obtain first
Trial-specific product/composition/content tables and formulation contributions
Further research
Material needed: Trial-specific product/composition/content tables and formulation contributions. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Curcuma longa-derived curcumin/curcuminoids and oral-formulation classification must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Curcuma longa-derived curcumin/curcuminoids and oral-formulation classification is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N03 · How are piperine, diet and exercise combination effects distinguished?

Current findings
The original keeps piperine combinations separate and warns against assigning piperine, diet or exercise combination effects to curcumin alone.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Trial-specific piperine, lifestyle measures, other ingredients and interventions shared by both arms remain unverified.
Required materials and conditions
Separating curcumin alone from absorption-enhancer/lifestyle combinations
Materials to obtain first
Trial-specific composition, accompanying diet/exercise and shared-care tables
Further research
Material needed: Trial-specific composition, accompanying diet/exercise and shared-care tables. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Separating curcumin alone from absorption-enhancer/lifestyle combinations must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Separating curcumin alone from absorption-enhancer/lifestyle combinations is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N04 · Are oral supplementation, turmeric and topical oral products the same intervention?

Current findings
The original intervention is oral curcumin/curcuminoid supplementation. It warns against treating products as interchangeable.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Direct body-weight effects of ordinary turmeric powder, foods, rinses, gels or particular formulations remain unverified.
Required materials and conditions
Distinguishing swallowed supplements from conventional turmeric, topical products and special formulations
Materials to obtain first
Original trials using the same product and route
Further research
Material needed: Original trials using the same product and route. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Distinguishing swallowed supplements from conventional turmeric, topical products and special formulations must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Distinguishing swallowed supplements from conventional turmeric, topical products and special formulations is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N05 · Were overweight, obesity and metabolic-disease populations distinguished?

Current findings
The retained use conditions describe adults with overweight, obesity or obesity-related metabolic disease. The original claim concerns body weight in kg in adults with overweight or obesity.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Trial-specific diseases, eligibility, baseline body weight/BMI and population-subgroup contributions remain unverified.
Required materials and conditions
Trial-specific weight status, obesity-related metabolic disease and baseline BMI/body weight
Materials to obtain first
Included-study populations/baseline characteristics and eligibility criteria
Further research
Material needed: Included-study populations/baseline characteristics and eligibility criteria. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Trial-specific weight status, obesity-related metabolic disease and baseline BMI/body weight must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Trial-specific weight status, obesity-related metabolic disease and baseline BMI/body weight is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N06 · What doses were used, and is an optimum established?

Current findings
The original dose record states that doses varied across trials and no single optimum was established.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Trial-specific mg/day, administration frequency, curcuminoid content, adherence and direct dose-specific effects remain unverified.
Required materials and conditions
Trial-specific administered doses, constituent content, frequency and adherence
Materials to obtain first
Original-trial administration/constituent-content tables
Further research
Material needed: Original-trial administration/constituent-content tables. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Trial-specific administered doses, constituent content, frequency and adherence must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Trial-specific administered doses, constituent content, frequency and adherence is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N07 · Which weight results across weeks to months were pooled?

Current findings
The original duration is weeks to months, varying by trial.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
The duration distribution, body-weight measurement timepoints, final-value/change-score selection and persistence after discontinuation remain unverified.
Required materials and conditions
Trial-specific treatment duration, measurement visits and end/follow-up timepoints
Materials to obtain first
Trial-specific visits/durations, follow-up and extraction-timepoint tables
Further research
Material needed: Trial-specific visits/durations, follow-up and extraction-timepoint tables. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Trial-specific treatment duration, measurement visits and end/follow-up timepoints must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Trial-specific treatment duration, measurement visits and end/follow-up timepoints is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N08 · What did placebo or control management involve?

Current findings
The original comparator is placebo or control management.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Trial-specific placebo/management types, concomitant obesity treatment and care shared by both arms remain unverified.
Required materials and conditions
Comparator, shared treatment, lifestyle management and differences between arms
Materials to obtain first
Original-trial comparator/shared-management tables
Further research
Material needed: Original-trial comparator/shared-management tables. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Comparator, shared treatment, lifestyle management and differences between arms must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Comparator, shared treatment, lifestyle management and differences between arms is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N09 · How are changes in diet, exercise and medicines distinguished from curcumin?

Current findings
The original explanation describes diverse products, populations and accompanying lifestyle measures.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Arm-specific diet, exercise, medicine changes and handling of confounding/imbalance remain unverified.
Required materials and conditions
Diet/exercise, weight-management/metabolic medicines, cointerventions and changes
Materials to obtain first
Trial-specific concomitant-treatment, lifestyle and metabolic-medicine records
Further research
Material needed: Trial-specific concomitant-treatment, lifestyle and metabolic-medicine records. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Diet/exercise, weight-management/metabolic medicines, cointerventions and changes must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Diet/exercise, weight-management/metabolic medicines, cointerventions and changes is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N10 · Is body weight in kg the same outcome as BMI, waist circumference or body fat?

Current findings
The original principal endpoint is body-weight change in kg. The supplementary explanation keeps BMI, waist circumference and body fat separate.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Weight measurement/change definitions, other endpoint-specific results and contributing counts remain unverified.
Required materials and conditions
Separating weight change in kg from other anthropometric endpoints
Materials to obtain first
Endpoint-specific definitions, units and extracted results
Further research
Material needed: Endpoint-specific definitions, units and extracted results. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Separating weight change in kg from other anthropometric endpoints must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Separating weight change in kg from other anthropometric endpoints is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N11 · What are the overall weight estimate and interval?

Current findings
The retained overall body-weight result is MD −0.59 kg, 95% CI −0.81 to −0.36.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Individual contributing trial effects, participant denominators, timepoints and final-value/change definitions remain unverified.
Required materials and conditions
Body-weight MD in kg, 95% CI, contributing trials/denominators and measurement timepoints
Materials to obtain first
Body-weight forest plot, extraction table, denominators/timepoints and analysis methods
Further research
Material needed: Body-weight forest plot, extraction table, denominators/timepoints and analysis methods. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Body-weight MD in kg, 95% CI, contributing trials/denominators and measurement timepoints must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Body-weight MD in kg, 95% CI, contributing trials/denominators and measurement timepoints is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N12 · What is the scope of the enhanced-formulation −0.80 kg result?

Current findings
The original result also records enhanced formulations at −0.80 kg, interval −1.38 to −0.23; the reader answer also describes 0.80 kg.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Which enhanced formulations/participants contributed, contributing trial counts, interval calculation/confidence-level details and subgroup plans remain unverified.
Required materials and conditions
Enhanced-formulation classification, contributing counts, MD, interval, population/dose/duration
Materials to obtain first
Enhanced-formulation classification, subgroup forest plot, denominators and analysis plan
Further research
Material needed: Enhanced-formulation classification, subgroup forest plot, denominators and analysis plan. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Enhanced-formulation classification, contributing counts, MD, interval, population/dose/duration must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Enhanced-formulation classification, contributing counts, MD, interval, population/dose/duration is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N13 · Is this direct evidence that enhanced formulations outperform conventional forms?

Current findings
The original records the overall pooled value and enhanced-formulation subgroup value, without a direct between-formulation comparison estimate.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Direct conventional-versus-enhanced comparisons, subgroup interaction and control of population/duration differences remain unverified.
Required materials and conditions
Direct randomized comparisons between formulations, interaction tests and shared population/dose conditions
Materials to obtain first
Direct formulation-comparison studies and subgroup comparison plans/tests
Further research
Material needed: Direct formulation-comparison studies and subgroup comparison plans/tests. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Direct randomized comparisons between formulations, interaction tests and shared population/dose conditions must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Direct randomized comparisons between formulations, interaction tests and shared population/dose conditions is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N14 · What can this table establish about BMI?

Current findings
The original supplementary explanation keeps BMI separate from the weight-in-kg verdict.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
BMI effects, intervals, contributing trials/denominators and timepoints remain unverified.
Required materials and conditions
BMI units, measurement timepoints, contributing trials and effects/intervals
Materials to obtain first
Separate BMI results/forest plot and definitions
Further research
Material needed: Separate BMI results/forest plot and definitions. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on BMI units, measurement timepoints, contributing trials and effects/intervals must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on BMI units, measurement timepoints, contributing trials and effects/intervals is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N15 · How is waist circumference retained as a separate outcome?

Current findings
The original supplementary explanation separates waist circumference from the weight-in-kg verdict.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Waist values, measurement procedures and contributing trials/denominators remain unverified.
Required materials and conditions
Waist-circumference units, measurement sites, timepoints and effects/intervals
Materials to obtain first
Separate waist-circumference definitions/results and contribution lists
Further research
Material needed: Separate waist-circumference definitions/results and contribution lists. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Waist-circumference units, measurement sites, timepoints and effects/intervals must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Waist-circumference units, measurement sites, timepoints and effects/intervals is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N16 · Can the weight estimate stand in for body-fat reduction?

Current findings
The original supplementary explanation keeps body fat separate from body weight in kg.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Body-fat values, measurement techniques, contributing trials/denominators and timepoints remain unverified.
Required materials and conditions
Body-fat measurement methods, units, denominators, timepoints and effects
Materials to obtain first
Separate body-fat measurement/effect tables
Further research
Material needed: Separate body-fat measurement/effect tables. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Body-fat measurement methods, units, denominators, timepoints and effects must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Body-fat measurement methods, units, denominators, timepoints and effects is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N17 · What counts are the 14 meta-analyses and 50 RCTs?

Current findings
The original research description refers to 14 existing meta-analyses and an updated search identifying 50 RCTs with weight-in-kg results. The evidence sample description is 50 RCTs; 21 at high risk.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Original inclusion lists, overlap between updated/existing material, weight-contributing trial lists and inclusion relationships among meta-analyses remain unverified.
Required materials and conditions
Separating umbrella reviews, updated RCTs and endpoint-specific contributions
Materials to obtain first
Lists of the 14 reviews/50 trials, overlap relationships and endpoint contributions
Further research
Material needed: Lists of the 14 reviews/50 trials, overlap relationships and endpoint contributions. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Separating umbrella reviews, updated RCTs and endpoint-specific contributions must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Separating umbrella reviews, updated RCTs and endpoint-specific contributions is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N18 · How many participants were randomized, analyzed and completed across 50 trials?

Current findings
The current sample description records only 50 trials and 21 at high risk.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Unique participant totals, arm/trial-specific randomized, analyzed and completed counts, and body-weight/enhanced-formulation denominators remain unverified.
Required materials and conditions
Overall/trial-specific randomized, analyzed, completed and endpoint/subgroup denominators
Materials to obtain first
Original-trial flow, denominators and meta-analysis contributing-participant tables
Further research
Material needed: Original-trial flow, denominators and meta-analysis contributing-participant tables. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Overall/trial-specific randomized, analyzed, completed and endpoint/subgroup denominators must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Overall/trial-specific randomized, analyzed, completed and endpoint/subgroup denominators is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N19 · Did the same trial recur across reviews and papers?

Current findings
The source retains 1 umbrella-review/updated-meta-analysis report.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Multiple papers from the same trial, participant overlap, overlap among the 14 reviews and subgroup overlap remain unverified.
Required materials and conditions
Original-trial IDs, multiple reports, follow-up/registration and review inclusion relationships
Materials to obtain first
Relationships among included trials, reports and registrations
Further research
Material needed: Relationships among included trials, reports and registrations. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Original-trial IDs, multiple reports, follow-up/registration and review inclusion relationships must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Original-trial IDs, multiple reports, follow-up/registration and review inclusion relationships is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N20 · When and how far did the updated search extend?

Current findings
The original mentions an umbrella review and updated searching.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
The actual search cutoff, databases/strategies, unpublished-material searching, language/formulation restrictions and selection flow remain unverified.
Required materials and conditions
Search date, databases, strategies, registration/unpublished material and formulation/population eligibility
Materials to obtain first
Meta-analysis search strategies, eligibility, selection flow and search dates
Further research
Material needed: Meta-analysis search strategies, eligibility, selection flow and search dates. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Search date, databases, strategies, registration/unpublished material and formulation/population eligibility must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Search date, databases, strategies, registration/unpublished material and formulation/population eligibility is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N21 · Which original-trial weight values were extracted, and how?

Current findings
The retained use conditions describe body-weight change in kg; the evidence records body weight in kg and pooled MD.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Original/final/change/adjusted-value choices, timepoint selection, multi-arm handling, SD/missing-data extraction and unit conversion remain unverified.
Required materials and conditions
Final/change values, kg units, multiple timepoints, multiple arms, adjustment and duplicate selection
Materials to obtain first
Body-weight extraction, original result tables and analysis-code explanation
Further research
Material needed: Body-weight extraction, original result tables and analysis-code explanation. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Final/change values, kg units, multiple timepoints, multiple arms, adjustment and duplicate selection must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Final/change values, kg units, multiple timepoints, multiple arms, adjustment and duplicate selection is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N22 · How were MD and between-study heterogeneity estimated?

Current findings
The original result records MD and intervals; its explanation describes diversity in products, populations and lifestyles.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Fixed/random models, weights, I²/τ², prediction intervals and heterogeneity exploration remain unverified.
Required materials and conditions
Pooling model, weights, heterogeneity, prediction intervals and subgroups
Materials to obtain first
Statistical methods, forest plot, heterogeneity/prediction intervals and subgroup plans
Further research
Material needed: Statistical methods, forest plot, heterogeneity/prediction intervals and subgroup plans. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Pooling model, weights, heterogeneity, prediction intervals and subgroups must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Pooling model, weights, heterogeneity, prediction intervals and subgroups is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N23 · What are the 21 high-risk trials and original 42% description?

Current findings
The evidence sample description records 21 trials at high risk of bias; the key-point description refers to 21 trials, and the grade rationale describes 42% of original trials as high risk.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Which 21 trials, assessment tools/domains/procedures, weight-outcome contributions and sensitivity analyses remain unverified.
Required materials and conditions
Trial-specific risk assessment, tools/domains and contribution weights
Materials to obtain first
Original risk-assessment tables, tools and endpoint links
Further research
Material needed: Original risk-assessment tables, tools and endpoint links. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Trial-specific risk assessment, tools/domains and contribution weights must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Trial-specific risk assessment, tools/domains and contribution weights is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N24 · What were trial-specific randomization, masking and effects of interest?

Current findings
The original design is described as a meta-analysis of RCTs.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Randomization/concealment, masking, ITT/PP, baseline balance and endpoint limitations across the 50 trials remain unverified.
Required materials and conditions
Trial-specific allocation/concealment, masking, effects of interest and baseline balance
Materials to obtain first
Original-trial methods and allocation/analysis tables
Further research
Material needed: Original-trial methods and allocation/analysis tables. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Trial-specific allocation/concealment, masking, effects of interest and baseline balance must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Trial-specific allocation/concealment, masking, effects of interest and baseline balance is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N25 · How were attrition, nonadherence and missing weight measurements handled?

Current findings
The current summary does not contain trial-specific attrition, adherence or missing-data information.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Trial-specific missingness, reasons, handling, deviations/adherence, sensitivity analyses and their incorporation into the meta-analysis remain unverified.
Required materials and conditions
Arm-specific attrition, adherence, missing-data handling and weight-analysis denominators
Materials to obtain first
Original-trial flow, adherence and missing-data/sensitivity tables
Further research
Material needed: Original-trial flow, adherence and missing-data/sensitivity tables. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Arm-specific attrition, adherence, missing-data handling and weight-analysis denominators must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Arm-specific attrition, adherence, missing-data handling and weight-analysis denominators is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N26 · What are the results for high-risk/small trials and publication bias?

Current findings
The source describes 21 high-risk trials alongside a small pooled effect.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Results excluding high-risk trials, leave-one-out analyses, small-study/publication bias and effects of missing trials remain unverified.
Required materials and conditions
High-risk exclusions, small studies, missing/publication bias and influence analyses
Materials to obtain first
Sensitivity/influence, missing-report and publication-bias material
Further research
Material needed: Sensitivity/influence, missing-report and publication-bias material. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on High-risk exclusions, small studies, missing/publication bias and influence analyses must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on High-risk exclusions, small studies, missing/publication bias and influence analyses is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N27 · Do PROSPERO plans correspond to weight/subgroup analyses?

Current findings
The retained design describes a preregistered umbrella review/meta-analysis; funding/bibliography record PROSPERO CRD42022321112.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
PROSPERO content/registration dates, plan amendments, planned analyses/endpoint hierarchy and multiplicity remain unverified.
Required materials and conditions
Registration content, dated plans, body weight/BMI/waist/enhanced formulations and amendments
Materials to obtain first
PROSPERO content/history, plans and analysis lists
Further research
Material needed: PROSPERO content/history, plans and analysis lists. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Registration content, dated plans, body weight/BMI/waist/enhanced formulations and amendments must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Registration content, dated plans, body weight/BMI/waist/enhanced formulations and amendments is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N28 · Are the statistical signal and clinical meaning of 0.59 kg the same?

Current findings
The original reader answer describes a statistical signal without large weight loss. Its key-point description states that the mean is below 1 kg, and the grade rationale says it falls below a clinical threshold.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
The original threshold's definition/basis, population-specific importance, weight-loss maintenance and patient-important outcomes remain unverified.
Required materials and conditions
Effects/intervals, original interpretation, patient importance, baseline weight and persistence
Materials to obtain first
Prespecified clinical importance, baseline/maintenance and patient-important outcomes
Further research
Material needed: Prespecified clinical importance, baseline/maintenance and patient-important outcomes. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Effects/intervals, original interpretation, patient importance, baseline weight and persistence must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Effects/intervals, original interpretation, patient importance, baseline weight and persistence is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N29 · What is retained here from the original independence narrative?

Current findings
The original counterview describes recurring reduction directions across independent trials/umbrella review. The original R2/I2 axes are retained.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Team independence, direct replication with the same formulation, unique trials/participant counts and meta-analysis independence remain unverified in this externally unread scope.
Required materials and conditions
Unique trials/teams, question/formulation correspondence and overlap among meta-analyses
Materials to obtain first
Original-trial families, teams/support relationships and exact formulation/endpoint lists
Further research
Material needed: Original-trial families, teams/support relationships and exact formulation/endpoint lists. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Unique trials/teams, question/formulation correspondence and overlap among meta-analyses must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Unique trials/teams, question/formulation correspondence and overlap among meta-analyses is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N30 · Are PMID, DOI, PROSPERO and the stored summary distinguished?

Current findings
The original citation is Unhapipatpong et al., Am J Clin Nutr.2023;117:1005-1016, PMID36898635, DOI10.1016/j.ajcnut.2023.03.006, PROSPERO CRD42022321112. The material read is the stored JSON.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
External article abstracts/full texts, PROSPERO, original trials and related original material remain unread, with no access attempt.
Required materials and conditions
Original-report bibliography, registration wording, external-unread scope and stored JSON
Materials to obtain first
Articles, registration and supplementary/original-trial material corresponding to the citation
Further research
Material needed: Articles, registration and supplementary/original-trial material corresponding to the citation. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Original-report bibliography, registration wording, external-unread scope and stored JSON must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Original-report bibliography, registration wording, external-unread scope and stored JSON is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N31 · What are the nongovernmental support and product/author roles?

Current findings
The retained funding description records nongovernmental research support; PROSPERO CRD42022321112.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Supporting institutions/amounts, product support, employee authorship, conflicts and support roles in individual original trials remain unverified.
Required materials and conditions
Cash/product support, affiliations/conflicts and meta-analysis/original-trial roles
Materials to obtain first
Original meta-analysis/trial funding, conflict, author and product-support disclosures
Further research
Material needed: Original meta-analysis/trial funding, conflict, author and product-support disclosures. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Cash/product support, affiliations/conflicts and meta-analysis/original-trial roles must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Cash/product support, affiliations/conflicts and meta-analysis/original-trial roles is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N32 · How do original dates differ from the preparation timestamp?

Current findings
The original evidence date is 2026-09-08; the English correction is dated 2026-09-14. The meta-analysis bibliography is dated 2023.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Actual original-meta-analysis search dates, current external-reading dates and completed latest-search dates remain unverified/unrecorded.
Required materials and conditions
Original evidence date, correction date, meta-analysis publication/search and preparation timestamp
Materials to obtain first
Original search, receipt, publication and amendment-event records
Further research
Material needed: Original search, receipt, publication and amendment-event records. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Original evidence date, correction date, meta-analysis publication/search and preparation timestamp must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Original evidence date, correction date, meta-analysis publication/search and preparation timestamp is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N33 · How are generic English wording and the 1-field correction retained?

Current findings
The English reader answer records 0.59/0.80 kg. Generic explanations remain in English sample, funding, endpoint, result and evidence-weight fields; the correction describes changing 1 field.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Which field changed, its before/after values and detailed numerical/original-source correspondence in English still await review.
Required materials and conditions
Korean/English results, generic English evidence wording and before/after correction records
Materials to obtain first
Complete before/after English-correction originals and result translation
Further research
Material needed: Complete before/after English-correction originals and result translation. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Korean/English results, generic English evidence wording and before/after correction records must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Korean/English results, generic English evidence wording and before/after correction records is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N34 · What is the role of C54, historical cross-checking and axes here?

Current findings
The original C54/Caution, B/S/R2/I2/E~/B2/C0 axes and historical independent Codex cross-check wording are preserved in the source.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Current content review, new clinical validation and methodology certification remain incomplete.
Required materials and conditions
Original grade, score, safety, axes, grade decision and empty values
Materials to obtain first
The original verdict and subsequent authorized correction events
Further research
Material needed: The original verdict and subsequent authorized correction events. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Original grade, score, safety, axes, grade decision and empty values must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Original grade, score, safety, axes, grade decision and empty values is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N35 · For which events and denominators were gastrointestinal complaints reported?

Current findings
The retained safety wording describes gastrointestinal complaints as the main issue in short trials.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Event types, arm-specific event/person counts, harm denominators, collection/discontinuation and original-trial durations remain unverified.
Required materials and conditions
Event definitions/collection, arm-specific events/denominators, discontinuation/missingness and duration
Materials to obtain first
Original-trial adverse events/discontinuations, collection and arm-specific harm tables
Further research
Material needed: Original-trial adverse events/discontinuations, collection and arm-specific harm tables. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Event definitions/collection, arm-specific events/denominators, discontinuation/missingness and duration must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Event definitions/collection, arm-specific events/denominators, discontinuation/missingness and duration is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N36 · What is known about formulation-specific safety beyond short-term use?

Current findings
The original safety wording states that long-term/high-dose safety and medicine interactions are not adequately established by formulation.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Original material on formulation-specific long-term/rare harms, high doses, vulnerable groups and actual interactions remains unverified.
Required materials and conditions
Longer-term/high-dose use, formulation/absorption, vulnerable groups and medicine interactions
Materials to obtain first
Longer follow-up, formulation/dose-specific harms and interaction material
Further research
Material needed: Longer follow-up, formulation/dose-specific harms and interaction material. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Longer-term/high-dose use, formulation/absorption, vulnerable groups and medicine interactions must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Longer-term/high-dose use, formulation/absorption, vulnerable groups and medicine interactions is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N37 · Are harm timing, comparisons, alternative causes and independent cases available?

Current findings
The current manuscript retains only general short-term gastrointestinal/long-term interaction precautions.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Individual event timing, causality/alternative causes, between-group risks, independent harm cases and report families remain unverified.
Required materials and conditions
Onset/recovery, discontinuation/re-exposure, comparator/concomitant medicines and case families
Materials to obtain first
Individual-event timing, concomitant/alternative explanations, between-group harms and unique-case material
Further research
Material needed: Individual-event timing, concomitant/alternative explanations, between-group harms and unique-case material. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Onset/recovery, discontinuation/re-exposure, comparator/concomitant medicines and case families must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Onset/recovery, discontinuation/re-exposure, comparator/concomitant medicines and case families is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N38 · Does enhanced bioavailability cause the weight effect?

Current findings
The source records the enhanced-formulation weight subgroup value and warns against product interchangeability.
Verification status
Unverified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Absorption measurement, relationships between absorption changes and weight, direct formulation comparisons and causal mechanisms remain unverified.
Required materials and conditions
Formulation-specific exposure/absorption, direct weight comparisons and alternative explanations
Materials to obtain first
Formulation-specific exposure/absorption and direct clinical outcomes
Further research
Material needed: Formulation-specific exposure/absorption and direct clinical outcomes. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Formulation-specific exposure/absorption, direct weight comparisons and alternative explanations must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Formulation-specific exposure/absorption, direct weight comparisons and alternative explanations is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01

N39 · How are the stored summary and unread materials connected?

Current findings
The full stored JSON was read for preparation, with the original PubMed citation URL retained. External material remains unread, with no access attempt.
Verification status
Partly verified
Materials actually read
The retained Korean and English summary and bibliography were read. External abstracts, full texts, PROSPERO, original-trial, extraction, analysis, harm and support material remain unread, with no access attempt.
Why unverified
Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information
Full texts, PROSPERO, original-trial, extraction, statistical, harm and support material remain unverified; content review remains incomplete.
Required materials and conditions
Material-specific acquisition/reading, original citation links and condition/evidence-change events
Materials to obtain first
Original material/corrections supplied or separately authorized
Further research
Material needed: Original material/corrections supplied or separately authorized. This records needed materials; no new research was executed.
Remaining uncertainty
Gaps remain in product/population/dose/duration-specific direct effects, pooled/subgroup analyses, denominators, overlap, measurement, missingness, heterogeneity, importance, harms and support. Original numbers, grades and historical independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification
Original records on Material-specific acquisition/reading, original citation links and condition/evidence-change events must link to the relevant report, trial, review, participant, formulation, endpoint, timepoint, units and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed
Material on Material-specific acquisition/reading, original citation links and condition/evidence-change events is needed to connect the relevant formulation, oral route, population, endpoint/units, duration, pooled/subgroup scope, denominator, overlap or harm scope.
Application exceptions
Pooled means, enhanced-formulation subgroups and direct formulation comparisons remain distinct, as do weight versus other anthropometric endpoints and reviews/trials/participants. Differences, percentage weight loss, independent-replication counts, optimum doses, guaranteed loss, obesity-treatment replacement and safety certification are not newly calculated or inferred.
Referenced methods
Existing principles distinguish formulation, oral route, population, endpoint/units, duration, comparator, pooled/subgroup estimates, denominators, overlap, support and harms in the retained curcumin weight record.

Related sources R01